山东大学学报（医学版） ›› 2014, Vol. 52 ›› Issue (8): 6-13.doi: 10.6040/j.issn.1671-7554.0.2013.764
王晗1, 石莎1,2, 陈飞雪1, 李月月1, 曹静1, 左秀丽1, 李延青1
WANG Han1, SHI Sha1,2, CHEN Feixue1, LI Yueyue1, CAO Jing1, ZUO Xiuli1, LI Yanqing1
摘要： 目的 应用共聚焦激光显微内镜（CLE）在体评价非甾体抗炎药（NSAIDs）相关胃病中黏膜屏障功能障碍，探索替普瑞酮和雷贝拉唑对急性胃黏膜损伤预防与治疗的作用机制。方法 建立CLE急性胃黏膜损伤评分系统，在体评价NSAIDs相关急性胃黏膜损伤及药物干预效果，测定胃黏膜中occludin及ZO-1的表达水平。结果 NSAIDs相关胃病模型组黏膜损伤评分明显高于正常组，ZO-1与occludin表达明显减少。而药物预防组与治疗组损伤评分均明显降低，紧密连接蛋白表达则明显增多。结论 CLE可以客观、实时、准确地评价NSAIDs相关胃黏膜损伤中黏膜上皮细胞损伤及黏膜通透性的改变。NSAIDs可以引起occludin和ZO-1表达缺失，导致黏膜屏障功能障碍，替普瑞酮和雷贝拉唑可以通过抑制occludin和ZO-1的表达缺失，从而改善黏膜屏障功能。
中图分类号:
| [1] Brooks P, Emery P, Evans J F, et al. Interpreting the clinical significance of the differential inhibition of COX-1 and COX-2[J]. Rheumatology, 1999, 38(8): 779-788. [2] Bedson J, Whitehurst T, Lewis M, et al. Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease[J]. Br J Gen Pract, 2001, 51(473): 1001-1003. [3] Brunelli C, Amici C, Angelini M, et al. The non-steroidal anti-inflammatory drug indomethacin activates the eIF2alpha kinase PKR, causing a translational block in human colorectal cancer cells[J]. Biochem J, 2012, 443(2): 379-386. [4] Brady R R, Loveridge C J, Dunlop M G, et al. C-Src dependency of NSAID-induced effects on NF-kappaB-mediated apoptosis in colorectal cancer cells[J]. Carcinogenesis, 2011, 32(7): 1069-1077. [5] Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present and future[J]. Am J Med, 2001, 110(1A): 4S-7S. [6] Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient[J]. Gastroenterology, 2001, 120(3): 594-606. [7] Allison M C, Howatson A G, Torrance C J, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs[J]. N Engl J Med, 1992, 327(11): 749-754. [8] Fries J F, Williams C A, Bloch D A, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models[J]. Am J Med, 1991, 91(3): 213-222. [9] Dubois R W, Melmed G Y, Henning J M, et al. Risk of Upper Gastrointestinal Injury and Events in Patients Treated With Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy: An Appraisal of the Literature[J]. J Clin Rheumatol, 2004, 10(4): 178-189. [10] Takeuchi K, Tanaka A, Hayashi Y, et al. Functional mechanism underlying COX-2 expression following administration of indomethacin in rat stomachs: importance of gastric hypermotility[J]. Dig Dis Sci, 2004, 49(2): 180-187. [11] Takeuchi K, Tanaka A, Hayashi Y, et al. COX inhibition and NSAID-induced gastric damage-roles in various pathogenic events[J]. Curr Top Med Chem, 2005, 5(5): 475-486. [12] Banerjee D, Bhattacharya S, Bandyopadhyay S K, et al. Biochemical mechanism of healing activity of the natural phenolic, allylpyrocatechol against indomethacin-induced gastric ulceration in mice[J]. Dig Dis Sci, 2008, 53(11): 2868-2877. [13] Brzozowski T, Tarnawski A, Hollander D, et al. Comparison of prostaglandin and cimetidine in protection of isolated gastric glands against indomethacin injury[J]. J Physiol Pharmacol, 2005, 56 Suppl 5: 75-88. [14] Nagano Y, Matsui H, Muramatsu M, et al. Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells[J]. Dig Dis Sci, 2005, 50 Suppl 1: S76-83. [15] Yoshikawa T, Naito Y, Kishi A, et al. Role of active oxygen, lipid peroxidation, and antioxidants in the pathogenesis of gastric mucosal injury induced by indomethacin in rats[J]. Gut, 1993, 34(6): 732-737. [16] Chiou S K, Mandayam S. NSAIDs enhance proteasomic degradation of survivin, a mechanism of gastric epithelial cell injury and apoptosis[J]. Biochem Pharmacol, 2007, 74(10): 1485-95. [17] Nishida T, Yabe Y, Fu H Y, et al. Geranylgeranylacetone induces cyclooxygenase-2 expression in cultured rat gastric epithelial cells through NF-kappaB[J]. Dig Dis Sci, 2007, 52(8): 1890-1896. [18] Okazaki M, Shimizu I, Ishikawa M, et al. Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine[J]. J Med Invest, 2007, 54(1-2): 83-90. [19] Skoczylas T, Sarosiek I, Sostarich S, et al. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders[J]. Dig Dis Sci, 2003, 48(2): 322-328. [20] Ushijima H, Tanaka K, Takeda M, et al. Geranylgeranylacetone protects membranes against nonsteroidal anti-inflammatory drugs[J]. Mol Pharmacol, 2005, 68(4): 1156-1161. [21] Ohta Y, Kobayashi T, Inui K, et al. Preventive effect of teprenone on acute gastric mucosal lesion progression in compound 48/80-treated rats[J]. Eur J Pharmacol, 2004, 487(1-3): 223-232. [22] Dekigai H, Nakamura H, Bai J, et al. Geranylgeranylacetone promotes induction and secretion of thioredoxin in gastric mucosal cells and peripheral blood lymphocytes[J]. Free Radic Res, 2001, 35(1): 23-30. [23] Suemasu S, Tanaka K, Namba T, et al. A role for HSP70 in protecting against indomethacin-induced gastric lesions[J]. J Biol Chem, 2009, 284(29): 19705-19715. [24] Guth PH, Aures D, Paulsen G. Topical aspirin plus HCl gastric lesions in the rat: cytoprotective effect of prostaglandin, cimetidine, and probanthine[J]. Gastroenterology, 1979, 76(1): 88-93. [25] Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha ras oncogene product in normal, benign, and malignant human pancreatic tissue[J]. Hum Pathol, 1990, 21(6): 607-612. [26] Li C Q, Xie X J, Yu T, et al. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy[J]. Am J Gastroenterol, 2010, 105(6): 1391-1396. [27] Anderson J M, Van Itallie C M. Tight junctions and the molecular basis for regulation of paracellular permeability[J]. Am J Physiol, 1995, 269(4 Pt 1): G467-G475. |
| [1] | 刘海俊, 谢敏妍, 陈锦华, 冯洁萍, 邓振波. 替普瑞酮对大剂量激素 治疗患者上消化道的保护作用[J]. 山东大学学报（医学版）, 2014, 52(S2): 57-58. |
|
||
